by Stephen Levin
The idea of going where the money is may have worked for Willie Sutton. But for most medical device start-ups,...
Spine surgery has gone from the pariah of the orthopedic industry to that sector's fastest growing segment. Large companies have looked to capitalize on spine's rapid growth by acquiring their way into this space, a pattern of consolidation that has left the industry without a major pure play spinal company. SpineVision is looking to fill that void by developing a complete line of spinal products, starting with innovations on core technology, rather than relying on a typical start-up strategy of focusing on a particular device or clinical niche. The company's strategy will bring it immediately into competition with the market leaders' well-established product lines. But SpineVision is counting on experienced management and the current frustration among spine surgeons resulting from recent industry consolidation to attract physicians' attention.
by Stephen Levin
The idea of going where the money is may have worked for Willie Sutton. But for most medical device start-ups,...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.